Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 25.67% | 122.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 25.67% | 122.75% | |||
| Cost of Revenue | -11.67% | 78.31% | |||
| Gross Profit | 57.42% | 182.63% | |||
| SG&A Expenses | 65.64% | -25.35% | |||
| Depreciation & Amortization | -3.66% | -5.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.78% | 45.02% | |||
| Operating Income | 70.10% | 1,062.06% | |||
| Income Before Tax | -102.93% | 280.91% | |||
| Income Tax Expenses | 133.95% | 850.75% | |||
| Earnings from Continuing Operations | -134.62% | 256.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -134.62% | 256.06% | |||
| EBIT | 70.10% | 1,062.06% | |||
| EBITDA | 67.80% | 760.42% | |||
| EPS Basic | -134.59% | 255.88% | |||
| Normalized Basic EPS | -102.46% | 296.77% | |||
| EPS Diluted | -162.89% | 255.88% | |||
| Normalized Diluted EPS | -102.46% | 296.77% | |||
| Average Basic Shares Outstanding | 0.00% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||